Litcius/Paper detail

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo

Debashis Dutta, Malabendu Jana, Moumita Majumder, Susanta Mondal, Avik Roy, Kalipada Pahan

2021Nature Communications187 citationsDOIOpen Access PDF

Abstract

Pathways to control the spreading of α-synuclein (α-syn) and associated neuropathology in Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) are unclear. Here, we show that preformed α-syn fibrils (PFF) increase the association between TLR2 and MyD88, resulting in microglial activation. The TLR2-interaction domain of MyD88 (wtTIDM) peptide-mediated selective inhibition of TLR2 reduces PFF-induced microglial inflammation in vitro. In PFF-seeded A53T mice, the nasal administration of the wtTIDM peptide, NEMO-binding domain (wtNBD) peptide, or genetic deletion of TLR2 reduces glial inflammation, decreases α-syn spreading, and protects dopaminergic neurons by inhibiting NF-κB. In summary, α-syn spreading depends on the TLR2/MyD88/NF-κB pathway and it can be reduced by nasal delivery of wtTIDM and wtNBD peptides.

Topics & Concepts

In vivoIn vitroChemistryNF-κBCell biologyPharmacologySignal transductionBiologyBiochemistryGeneticsNeuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments
Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo | Litcius